Pyxis Oncology Appoints Thomas Civik as CEO and Chairman
Pyxis Oncology has announced that Thomas Civik will assume the roles of Chief Executive Officer and Chairman, effective September 4, 2026. This follows a leadership transition in which John Flavin, co-founder and founding chairman, moves to an independent director role while remaining on the board. Civik is expected to bring significant experience from his background in oncology drug development and commercialization. His appointment signals a strategic shift for Pyxis as it continues its focus on developing novel therapies for cancer patients. The change aims to strengthen leadership during what could be a pivotal phase of growth or clinical advancement for the company. The market may view this transition with cautious optimism, particularly if Civik's track record in oncology is seen as an asset that can drive value and progress for Pyxis.
Tickers: $PYXS
Topics: Biotech Leadership Oncology